What investigation should be performed in a patient with a raised prostate-specific antigen (PSA) level?

Investigation for Raised PSA

A patient with raised PSA requires digital rectal examination (DRE) followed by prostate biopsy if PSA is >4.0 ng/ml or if DRE is abnormal. 1

Initial Evaluation Algorithm

When encountering a patient with elevated PSA, proceed systematically:

1. Digital Rectal Examination (DRE)

Perform DRE immediately to assess for:

• Nodules
• Asymmetry
• Areas of increased firmness
• Overall prostate texture

If DRE reveals any abnormality (nodule, asymmetry, or firmness), proceed directly to biopsy regardless of PSA level. 2

2. PSA Threshold Decision Points

The evidence supports clear PSA cutoffs for biopsy decisions:

• PSA >4.0 ng/ml: Standard threshold for prostate biopsy 1, 2
• PSA 2.5-4.0 ng/ml: Consider biopsy based on additional risk factors (age, family history, race) 1
• PSA >50 ng/ml: 98.5% predictive of prostate cancer; biopsy highly recommended unless severe comorbidities preclude treatment 3

3. Consider PSA Derivatives for Borderline Cases (PSA 4-10 ng/ml)

When PSA is between 4-10 ng/ml and DRE is normal, calculate:

• PSA density (PSAD): Total PSA ÷ prostate volume

  • PSAD >0.10 ng/ml/cc warrants biopsy 4
  • PSAD <0.10 misses only 9% of cancers, but 87% of these are clinically significant 4

• Free/Total PSA ratio:

  • ≤25% free PSA: Proceed with biopsy (detects 95% of cancers while avoiding 20% of unnecessary biopsies) 5

  • 25% free PSA: Lower cancer risk, but consider patient age and other factors 5

• Prostate Health Index (PHI):

  • PHI >25 increases cancer probability 6

Biopsy Protocol

Initial Biopsy Technique

Perform extended-pattern transrectal ultrasound (TRUS)-guided biopsy with at least 12 cores (sextant medial and lateral peripheral zone plus any lesion-directed cores). 7

The standard sextant (6-core) biopsy is inadequate; extended 12-core protocols significantly improve cancer detection rates. 7

Role of MRI

For initial biopsy in standard-risk patients, routine MRI is not required. However, multiparametric MRI followed by targeted biopsy should be considered for:

• Persistently elevated PSA after negative initial biopsy 7
• High clinical suspicion despite negative biopsy 7
• MRI-targeted approaches detect 30% more high-risk cancers compared to systematic biopsy alone 7

Important Clinical Nuances

Age considerations: The probability of cancer increases significantly with age. Men 70+ years have substantially higher cancer rates than those 60-69 years old. 6 However, men >75 years or those with serious comorbidities may have limited benefit from screening. 1

Race-based risk: African-American men and those with first-degree relatives diagnosed at younger ages have higher prostate cancer risk and warrant more aggressive evaluation. 1

PSA velocity matters: A steady rise in PSA over time, particularly rapid increases, indicates higher cancer probability and more aggressive disease even when absolute values remain in "normal" ranges. 1

Common Pitfalls to Avoid

1. Don't rely solely on absolute PSA values - approximately 1 in 7 men with PSA <4.0 ng/ml have prostate cancer 1

2. Don't skip biopsy in very high PSA - despite 98.5% accuracy at PSA >50 ng/ml, biopsy provides definitive diagnosis and Gleason grading essential for treatment planning 3

3. Don't accept single negative biopsy as definitive - biopsies miss cancer in some cases; if clinical suspicion persists (rising PSA, abnormal DRE), consider repeat biopsy with MRI guidance 7, 1

4. Don't use PSAD cutoff of 0.15 - this threshold misses 7.9% of clinically important mid-to-high grade cancers; use 0.10 instead 4